381 related articles for article (PubMed ID: 2114942)
1. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
2. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
[TBL] [Abstract][Full Text] [Related]
3. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor.
Schiller JH; Witt PL; Storer B; Alberti D; Tombes MB; Arzoomanian R; Brown RR; Proctor RA; Voss SD; Spriggs DR
Cancer; 1992 Jan; 69(2):562-71. PubMed ID: 1728387
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy.
Schiller JH; Storer B; Willson JK; Borden EC
Cancer Treat Rep; 1987 Oct; 71(10):945-52. PubMed ID: 3115570
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
Witt PL; Ritch PS; Reding D; McAuliffe TL; Westrick L; Grossberg SE; Borden EC
Cancer Res; 1993 Nov; 53(21):5176-80. PubMed ID: 8221654
[TBL] [Abstract][Full Text] [Related]
8. Activation of 2',5'-oligoadenylate synthetase and B-2 microglobulin in cancer patients treated with partially pure gamma interferon: dependence of biological effect on administration route.
Rosenblum MG; Riso A; Gutterman JU
Cancer Chemother Pharmacol; 1986; 16(3):273-6. PubMed ID: 3084109
[TBL] [Abstract][Full Text] [Related]
9. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens.
Landmann R; Ludwig C; Wesp M; Fisscher A; Obrist R; Knüsli C; Denz H; Obrecht JP
J Interferon Res; 1992 Apr; 12(2):103-11. PubMed ID: 1374454
[TBL] [Abstract][Full Text] [Related]
10. Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle.
Schiller JH; Horisberger MA; Bittner G; Carlin JM; Storer B; Byrne GI; Willson JK; Borden EC
J Biol Response Mod; 1990 Aug; 9(4):368-77. PubMed ID: 2395002
[TBL] [Abstract][Full Text] [Related]
11. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly.
Schiller JH; Storer BE; Witt PL; Alberti D; Tombes MB; Arzoomanian R; Proctor RA; McCarthy D; Brown RR; Voss SD
Cancer Res; 1991 Mar; 51(6):1651-8. PubMed ID: 1998956
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
[TBL] [Abstract][Full Text] [Related]
13. Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma.
Paulnock DM; Havlin KA; Storer BM; Spear GT; Sielaff KM; Borden EC
J Interferon Res; 1989 Aug; 9(4):457-73. PubMed ID: 2502586
[TBL] [Abstract][Full Text] [Related]
14. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
Giosuè S; Casarini M; Ameglio F; Alemanno L; Saltini C; Bisetti A
Eur Respir J; 1996 Jan; 9(1):42-6. PubMed ID: 8834332
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of human lymphoblastoid interferon with whole body hyperthermia in advanced cancer.
Robins HI; Sielaff KM; Storer B; Hawkins MJ; Borden EC
Cancer Res; 1989 Mar; 49(6):1609-15. PubMed ID: 2647291
[TBL] [Abstract][Full Text] [Related]
16. In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma.
Kirkwood JM; Ernstoff MS; Trautman T; Hebert G; Nishida Y; Davis CA; Balzer J; Reich S; Schindler J; Rudnick SA
J Clin Oncol; 1990 Jun; 8(6):1070-82. PubMed ID: 2112184
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion.
Vadhan-Raj S; Nathan CF; Sherwin SA; Oettgen HF; Krown SE
Cancer Treat Rep; 1986 May; 70(5):609-14. PubMed ID: 3085930
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation of a synthetic mutant of beta-interferon.
Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
[TBL] [Abstract][Full Text] [Related]
20. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
